AI English summary of an SEC filing — figures as filed

The company said it appointed David P. Maughan, Senior Vice President, as Chief Operating Officer, DaVita Kidney Care, effective on September 15, 2024, after announcing the appointment on September 9, 2024.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Sep 13, 2024Period of report Sep 9, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said it appointed David P. Maughan, Senior Vice President, as Chief Operating Officer, DaVita Kidney Care, effective on September 15, 2024, after announcing the appointment on September 9, 2024.
DaVita said Maughan will succeed Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of September 15, 2024.
The company said Maughan, 47, served as Senior Vice President, Kidney Care, from November 2019 to September 2024 and joined DaVita in 2006. It also said there are no family relationships between Maughan and any director or executive officer.
DaVita said it set Maughan's annual base salary at $725,000 under its employment agreement with him, and set his target incentive bonus opportunity for 2024 at 100% of his base salary earned during 2024.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Chief Operating Officer Transition Announced

The company said it appointed David P. Maughan, Senior Vice President, as Chief Operating Officer, DaVita Kidney Care, effective on September 15, 2024, after announcing the appointment on September 9, 2024.

Source · Based on the filing body and exhibits

Succession From Michael D. Staffieri Transition

DaVita said Maughan will succeed Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of September 15, 2024.

Source · Based on the filing body and exhibits

Maughan Career and Related-Party Disclosure

The company said Maughan, 47, served as Senior Vice President, Kidney Care, from November 2019 to September 2024 and joined DaVita in 2006. It also said there are no family relationships between Maughan and any director or executive officer.

Source · Based on the filing body and exhibits

Compensation Terms in Maughan Employment Agreement

DaVita said it set Maughan's annual base salary at $725,000 under its employment agreement with him, and set his target incentive bonus opportunity for 2024 at 100% of his base salary earned during 2024.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.